208 related articles for article (PubMed ID: 26014937)
1. Validation of Sensititre Dry-Form Broth Microdilution Panels for Susceptibility Testing of Ceftazidime-Avibactam, a Broad-Spectrum-β-Lactamase Inhibitor Combination.
Jones RN; Holliday NM; Krause KM
Antimicrob Agents Chemother; 2015 Aug; 59(8):5036-9. PubMed ID: 26014937
[TBL] [Abstract][Full Text] [Related]
2. A Systematic Approach to the Selection of the Appropriate Avibactam Concentration for Use with Ceftazidime in Broth Microdilution Susceptibility Testing.
Bradford PA; Huband MD; Stone GG
Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29735568
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of ceftazidime, ceftaroline and aztreonam alone and in combination with avibactam against European Gram-negative and Gram-positive clinical isolates.
Testa R; Cantón R; Giani T; Morosini MI; Nichols WW; Seifert H; Stefanik D; Rossolini GM; Nordmann P
Int J Antimicrob Agents; 2015 Jun; 45(6):641-6. PubMed ID: 25748553
[TBL] [Abstract][Full Text] [Related]
4. Clinical activity of ceftazidime/avibactam against MDR Enterobacteriaceae and Pseudomonas aeruginosa: pooled data from the ceftazidime/avibactam Phase III clinical trial programme.
Stone GG; Newell P; Gasink LB; Broadhurst H; Wardman A; Yates K; Chen Z; Song J; Chow JW
J Antimicrob Chemother; 2018 Sep; 73(9):2519-2523. PubMed ID: 29912399
[TBL] [Abstract][Full Text] [Related]
5. Ceftazidime-avibactam activity when tested against ceftazidime-nonsusceptible Citrobacter spp., Enterobacter spp., Serratia marcescens, and Pseudomonas aeruginosa from Unites States medical centers (2011-2014).
Sader HS; Castanheira M; Farrell DJ; Flamm RK; Jones RN
Diagn Microbiol Infect Dis; 2015 Dec; 83(4):389-94. PubMed ID: 26162518
[TBL] [Abstract][Full Text] [Related]
6. Ceftazidime-Avibactam Antimicrobial Activity and Spectrum When Tested Against Gram-negative Organisms From Pediatric Patients: Results From the INFORM Surveillance Program (United States, 2011-2015).
Sader HS; Huband MD; Duncan LR; Flamm RK
Pediatr Infect Dis J; 2018 Jun; 37(6):549-554. PubMed ID: 29206750
[TBL] [Abstract][Full Text] [Related]
7.
Karlowsky JA; Kazmierczak KM; Bouchillon SK; de Jonge BLM; Stone GG; Sahm DF
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670424
[TBL] [Abstract][Full Text] [Related]
8.
Stone GG; Bradford PA; Tawadrous M; Taylor D; Cadatal MJ; Chen Z; Chow JW
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32071051
[TBL] [Abstract][Full Text] [Related]
9. Activity of ceftazidime/avibactam against problem Enterobacteriaceae and Pseudomonas aeruginosa in the UK, 2015-16.
Livermore DM; Meunier D; Hopkins KL; Doumith M; Hill R; Pike R; Staves P; Woodford N
J Antimicrob Chemother; 2018 Mar; 73(3):648-657. PubMed ID: 29228202
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of ceftazidime-avibactam and comparators against Enterobacterales and Pseudomonas aeruginosa isolates from Central Europe and Israel, 2014-2017 and 2018.
Kristóf K; Adámková V; Adler A; Gospodarek-Komkowska E; Rafila A; Billová S; Możejko-Pastewka B; Kiss F
Diagn Microbiol Infect Dis; 2021 Sep; 101(1):115420. PubMed ID: 34091111
[TBL] [Abstract][Full Text] [Related]
11. Assessment of 30/20-Microgram Disk Content versus MIC Results for Ceftazidime-Avibactam Tested against Enterobacteriaceae and Pseudomonas aeruginosa.
Sader HS; Rhomberg PR; Huband MD; Critchley IA; Stone GG; Flamm RK; Jones RN
J Clin Microbiol; 2018 Jun; 56(6):. PubMed ID: 29563198
[TBL] [Abstract][Full Text] [Related]
12. Avibactam confers susceptibility to a large proportion of ceftazidime-resistant Pseudomonas aeruginosa isolates recovered from cystic fibrosis patients.
Chalhoub H; Tunney M; Elborn JS; Vergison A; Denis O; Plésiat P; Kahl BC; Van Bambeke F; Tulkens PM
J Antimicrob Chemother; 2015 May; 70(5):1596-8. PubMed ID: 25587996
[No Abstract] [Full Text] [Related]
13. In vitro activity of ceftazidime/avibactam against urinary isolates from patients in a Phase 3 clinical trial programme for the treatment of complicated urinary tract infections.
Stone GG; Bradford PA; Yates K; Newell P
J Antimicrob Chemother; 2017 May; 72(5):1396-1399. PubMed ID: 28088768
[TBL] [Abstract][Full Text] [Related]
14. In vivo efficacy of humanized exposures of Ceftazidime-Avibactam in comparison with Ceftazidime against contemporary Enterobacteriaceae isolates.
MacVane SH; Crandon JL; Nichols WW; Nicolau DP
Antimicrob Agents Chemother; 2014 Nov; 58(11):6913-9. PubMed ID: 25223999
[TBL] [Abstract][Full Text] [Related]
15. Antimicrobial Activities of Ceftazidime-Avibactam and Comparator Agents against Clinical Bacteria Isolated from Patients with Cancer.
Hachem R; Reitzel R; Rolston K; Chaftari AM; Raad I
Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28115350
[TBL] [Abstract][Full Text] [Related]
16. In vitro antibacterial activity of the ceftazidime-avibactam combination against enterobacteriaceae, including strains with well-characterized β-lactamases.
Levasseur P; Girard AM; Miossec C; Pace J; Coleman K
Antimicrob Agents Chemother; 2015 Apr; 59(4):1931-4. PubMed ID: 25583732
[TBL] [Abstract][Full Text] [Related]
17. In vitro activity of ceftazidime-avibactam against Gram-negative isolates collected in 18 European countries, 2015-2017.
Stone GG; Seifert H; Nord CE
Int J Antimicrob Agents; 2020 Sep; 56(3):106045. PubMed ID: 32522673
[TBL] [Abstract][Full Text] [Related]
18. Comparison of methods to analyse susceptibility of German MDR/XDR Pseudomonas aeruginosa to ceftazidime/avibactam.
Schaumburg F; Bletz S; Mellmann A; Becker K; Idelevich EA
Int J Antimicrob Agents; 2019 Aug; 54(2):255-260. PubMed ID: 31071465
[TBL] [Abstract][Full Text] [Related]
19. Activity of ceftazidime-avibactam against fluoroquinolone-resistant Enterobacteriaceae and Pseudomonas aeruginosa.
Pitart C; Marco F; Keating TA; Nichols WW; Vila J
Antimicrob Agents Chemother; 2015; 59(6):3059-65. PubMed ID: 25753646
[TBL] [Abstract][Full Text] [Related]
20. Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12).
Sader HS; Farrell DJ; Castanheira M; Flamm RK; Jones RN
J Antimicrob Chemother; 2014 Oct; 69(10):2713-22. PubMed ID: 24917579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
